Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Benchmark Downgrades Emergent BioSolutions to Hold

Benchmark Downgrades Emergent BioSolutions to Hold

Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.

November 10, 2022

1 minute read

Benchmark analyst Robert Wasserman downgrades Emergent BioSolutions (NYSE:EBS) from Buy to Hold.

Peter Schiff Says DoJ Harassing Google With Antitrust Lawsuit: ‘Consumers Need Protection From Government…Not Private Companies’

January 25, 1:21 AM

Peter Schiff, chief economist and global strategist at Euro Pacific Capital, criticized antitrust laws at a time when the U.S.

March 24, 1:40 AM

Tesla Inc‘s (NASDAQ:TSLA) Model S and Model X will make their debut in South Korea at the 2023…

June 20, 10:00 AM

Across the recent three months, 19 analysts have shared their insights on Sage Therapeutics (NASDAQ:SAGE), expressing a variety…

October 25, 11:12 AM

GSK plc (NYSE:GSK) will transfer its NY-ESO cell therapy program and the right to the PRAME cell therapy program to Adaptimmune Therapeutics…